

3. Continued accessibility of RTECS® to the international scientific community. The Licensee must make RTECS® continuously available world-wide and market the Database in a variety of formats including, but not limited to on-line, CD-ROM, and the Internet.

4. Multiple point and free access to NIOSH of all RTECS® products. The Licensee will provide NIOSH research and information staff with multiple point and free access to RTECS® to accommodate NIOSH users at six NIOSH sites, maximum usage not to exceed 25 users.

5. NIOSH representation on editorial or policy board or committee. A NIOSH representative will be designated to serve on any editorial or policy board established for the Database to ensure that the interests of the Institute are considered. This representative will serve in a consultative capacity without decision-making authority.

General Terms

1. Ownership of the RTECS® trademark will be retained by NIOSH.

2. The licensing agreement can be terminated by either party.

3. Ownership of data files, microfiche, and other files. NIOSH will retain ownership of the last RTECS® Master File produced with NIOSH funds. The Licensee will retain ownership of all new data generated and indexed under this agreement. NIOSH will also retain ownership of the microfiche collection of the bibliographical references. The full hard copy collection of the same references will be delivered to the Licensee, along with the annual microfiche editions produced after 1987. In the event of a termination of the Licensing Agreement, the hard copy collection and annual microfiche additions will be returned to NIOSH.

4. Duration of agreement will be negotiated in the license.

5. In submitted proposals, each requirement shall be addressed individually.

Linda Rosenstock,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 00-25429 Filed 10-02-00; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (P.L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following council meeting.

Name: Advisory Council for the Elimination of Tuberculosis (ACET).

Times and Dates: 8:30 a.m.-5 p.m., October 18, 2000; 8:30 a.m.-12 p.m., October 19, 2000.

Place: Corporate Square, Building 8, 1st Floor Conference Room, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

Matters To Be Discussed: Agenda items include issues pertaining to the IOM Report on TB Elimination in the U.S. and other TB related topics.

Contact Person for More Information: Paulette Ford, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E-07, Atlanta, Georgia 30333, telephone 404/639-8008.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: September 27, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00-25322 Filed 10-2-00; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N-1224]

Agency Information Collection Activities; Announcement of OMB Approval; Submitting and Reviewing Complete Responses to Clinical Holds; Guidance for Industry

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Submitting and Reviewing Complete Responses to Clinical Holds; Guidance for Industry" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1482.

SUPPLEMENTARY INFORMATION: In the *Federal Register* of April, 13, 2000 (65 FR 19910), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0445. The approval expires on September 12, 2003. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: September 26, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00-25283 Filed 10-2-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.